John Matthew Koomen

Title: Innovations in Myeloma Monitoring by John Matthew Koomen

Introduction

John Matthew Koomen is a notable inventor based in Tampa, FL (US), recognized for his contributions to the field of medical diagnostics. He holds a total of 4 patents, focusing primarily on methods for monitoring conditions associated with antibody production, particularly multiple myeloma.

Latest Patents

Koomen's latest patents include groundbreaking methods and materials for diagnosing and monitoring myeloma using quantitative mass spectrometry. The subject invention concerns methods for diagnosing, monitoring the progress, and providing a prognosis for multiple myeloma and other conditions associated with antibody production in a person or animal. The methods utilize mass spectrometry for quantitative monitoring and detection of antibodies produced by plasma cells. This innovative approach can be utilized for diagnosis, monitoring, and prognosis of multiple myeloma, monoclonal gammopathy, and other immunological or hematological conditions. In addition to detecting and quantifying antibodies in a sample, other biological markers, such as serum albumin and beta-2-microglobulin, can also be detected and quantified. Thus, both antibody and serum albumin and/or beta-2-microglobulin are detected and quantified using mass spectrometry, allowing for a comprehensive diagnosis or prognosis based on the results.

Another significant patent by Koomen is a personalized method for monitoring conditions associated with antibody production. This method involves treating a biological sample comprising immunoglobulin from the subject to enzymatically cleave a target immunoglobulin associated with the plasma cell disorder into variable domain peptide fragments. These fragments are then measured by quantitative mass spectrometry to quantify the amount of the target immunoglobulin in the sample.

Career Highlights

Throughout his career, Koomen has made significant strides in the field of cancer research and diagnostics. He has worked at the H. Lee Moffitt Cancer Center and Research Institute, Inc., where he has contributed to advancing the understanding and treatment of multiple myeloma.

Collaborations

Koomen has collaborated with notable professionals in his field, including Elizabeth Renee Remily and Kaaron Benson. Their combined expertise has furthered the development of innovative diagnostic methods.

Conclusion

John Matthew Koomen's work in the field of myeloma monitoring exemplifies the impact of innovative thinking in medical diagnostics. His patents reflect a commitment to improving patient outcomes through advanced technology and